Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Constellation Energy Corporation (CEG) vs Heron Therapeutics Inc (HRTX) Price & Performance

Constellation Energy CorporationTrade
Heron Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

Constellation Energy Corporation vs Heron Therapeutics Inc — how do they compare? Constellation Energy Corporation trades at $279.76 (market cap $95.82B), while Heron Therapeutics Inc trades at $0.32 (market cap $63.41M). The key difference: Constellation Energy Corporation is far larger — about 1511.1× Heron Therapeutics Inc's market cap, and Constellation Energy Corporation pays a 0.63% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.

CEGHRTX
Market Cap
$95.82B$63.41M
Sector
EnergyHealth
52-Week High
$403.95$1.49
52-Week Low
$236.50$0.32
Enterprise Value
$119.82B$161.31M
Dividend Yield
0.63%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Constellation Energy Corporation

Constellation Energy (CEG) trades at $269.89, up 3.37% with a bullish technical outlook. The stock shows strong fundamentals with Q2 2026 EPS beating estimates at $2.55 versus $2.29 expected, and the company raised its 2026 guidance. Recent news highlights new power deals, including a Walmart PPA, and the acquisition of Calpine, positioning CEG to benefit from AI-driven electricity demand.

The outlook is positive with a consensus price target of $333.14, implying significant upside. Key opportunities include nuclear energy's role in the AI power boom and strong cash flow generation. Risks involve execution of growth initiatives and potential regulatory changes affecting the utilities sector.

Heron Therapeutics Inc

Heron Therapeutics (HRTX) trades at $0.49, down 1.64% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed earnings expectations with a $0.03 loss per share. Despite negative net income margins, HRTX maintains strong analyst support with 94.7% buy ratings. Recent news highlights patent litigation developments and quarterly earnings underperformance.

HRTX faces significant fundamental challenges with persistent losses and declining revenue projections, though analyst consensus remains overwhelmingly bullish. Investment opportunity exists if the company can achieve profitability and meet growth targets, but risks include ongoing operational losses, competitive pressures, and execution challenges in the biotechnology sector.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Constellation Energy Corporation

Constellation is the largest producer of carbon-free energy in the U.S. and a leading nuclear power plant operator. It provides sustainable electricity to millions of residential, public, and industrial customers.

Read more on CEG

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX